Xspray steams ahead

April 18, 2018
C Talk with CEO Per Andersson, Xspray Pharma

( click to play )

Since its successful listing in the autumn, Xspray has steamed ahead and has substantially bolstered its cash position through share issues

The product

Xspray has developed a technology that makes it possible to compete with current original cancer treatment drugs by developing specialist drugs based on known substances already available on the market


Xspray aims to license its products to large generic pharmaceutical companies, or to those companies that own and market the original drugs. Its products will be launched on the US market between 2020 and 2023

The potential

The PKI market segment in the US is expected to rise from sales of USD 10.9 billion in 2015 to USD 21.3 billion in 2020 and the company sees the potential for sales at the level of billions of kronor

Share price

Listed on First North under the ticker XSPRAY and trading at 60-65 SEK (20180426)

More information

If you want to know more about the company or want more information about current issues in the companies being interviewed contact us by email info@corneliapr.com or by joining Facebook-group Global Investors VIP


Share on facebook
Share on linkedin
Share on twitter
Share on google
Scroll Up